Vladimir Vorobyev

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 620 citations

Hematological Malignancy, Medicine, Immunology +6

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 231 citations

Hematological Malignancy, Surgical Oncology, Medicine +6

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

Arnon P. Kater, Carolyn Owen, Carol Moreno et al. · NEJM Evidence · 2022 · 208 citations

Immunology, Pathology, Fixed-duration Ibrutinib-venetoclax +16

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu et al. · New England Journal of Medicine · 2024 · 198 citations

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat et al. · Journal of Clinical Oncology · 2021 · 156 citations · Full text